SEC Form 4 · accession 0001237899-15-000025

REGENERON PHARMACEUTICALS, INC. · REGN

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Robert J Terifay

Officer — SVP Commercial

Period of report

Mar 16, 2015

Accepted (ET)

Mar 18, 2015 · 6:03 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000872589

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock	Mar 16, 2015	M	24,375	$30.63	A	44,404	D
Common Stock	Mar 16, 2015	F	1,679	$444.46	D	42,725	D
Common Stock	Mar 16, 2015	F	11,703	$444.46	D	31,022	D
Common Stock^F2	Mar 17, 2015	S	2,600	$448.01	D	28,422	D
Common Stock^F3	Mar 17, 2015	S	300	$448.87	D	28,122	D
Common Stock^F4	Mar 17, 2015	S	2,093	$450.18	D	26,029	D
Common Stock^F5	Mar 17, 2015	S	700	$450.95	D	25,329	D
Common Stock^F6	Mar 17, 2015	S	3,200	$452.61	D	22,129	D
Common Stock^F7	Mar 17, 2015	S	1,700	$453.28	D	20,429	D
Common Stock	Mar 17, 2015	S	400	$454.00	D	20,029	D
Common Stock	holding	—	—		—	1,651	I	By 401(k) Plan

Table II — derivative securities

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Non-Qualified Stock Option (right to buy)^F8	$30.63	Mar 16, 2015	M	24,375	D	—	Dec 14, 2020	Common Stock	24,375	29,236	D

Explanation of responses

F1Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
F2Represents volume-weighted average price of sales of 2,600 shares of Company stock on March 17, 2015 at prices ranging from $447.56 to $448.49. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 17, 2015 at each separate price.
F3Represents volume-weighted average price of sales of 300 shares of Company stock on March 17, 2015 at prices ranging from $448.60 to $449.01. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 17, 2015 at each separate price.
F4Represents volume-weighted average price of sales of 2,093 shares of Company stock on March 17, 2015 at prices ranging from $449.60 to $450.57. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 17, 2015 at each separate price.
F5Represents volume-weighted average price of sales of 700 shares of Company stock on March 17, 2015 at prices ranging from $450.75 to $451.09. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 17, 2015 at each separate price.
F6Represents volume-weighted average price of sales of 3,200 shares of Company stock on March 17, 2015 at prices ranging from $451.99 to $452.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 17, 2015 at each separate price.
F7Represents volume-weighted average price of sales of 1,700 shares of Company stock on March 17, 2015 at prices ranging from $452.99 to $453.73. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 17, 2015 at each separate price.
F8The option became exercisable with respect to all shares underlying the option on December 31, 2013, based upon the satisfaction by the company of certain performance criteria during the period ended December 31, 2013.